{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T10:26:48Z","timestamp":1781951208448,"version":"3.54.5"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>This case report describes the successful use of ofatumumab, a fully humanized anti-CD20 monoclonal antibody, in a 62 years old male with monoclonal gammopathy of undetermined significance (MGUS) associated chronic inflammatory demyelinating polyneuropathy. The patient presented with acute limb weakness, glove-like paresthesia, and respiratory involvement, alongside elevated anti-ganglioside antibodies (anti-GM4 IgM and IgG) and \u03bb-type IgM-M proteinemia. Despite initial therapies including intravenous immunoglobulin, efgartigimod, and immunosuppressants, he experienced recurrent relapses. Treatment with ofatumumab combined with methylprednisolone resulted in complete peripheral CD19+ B cell depletion, improved nerve conduction velocities, and sustained clinical remission. The findings highlight the efficacy of ofatumumab in targeting pathogenic CD20+ B cell clones, thereby disrupting autoantibody production implicated in immune mediated peripheral nerve injury. This case underscores the potential of B cell directed therapy for refractory MGUS associated neuropathies, offering a novel approach when conventional immunotherapies fail. Further multicenter studies are warranted to establish standardized protocols and optimize long term outcomes through combination regimens targeting both B cell and plasma cell compartments.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1633753","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:48:29Z","timestamp":1776059309000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Ofatumumab in chronic inflammatory demyelinating polyradiculoneuropathy associated with monoclonal gammopathy of undetermined significance: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Min","family":"Deng","sequence":"first","affiliation":[{"name":"Department of Neurology, Renmin Hospital of Wuhan University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Neurology, Renmin Hospital of Wuhan University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohong","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Neurology, Renmin Hospital of Wuhan University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Renmin Hospital of Wuhan University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Renmin Hospital of Wuhan University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa265","article-title":"Diagnostic challenges in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"143","author":"Eftimov","year":"2020","journal-title":"Brain"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-014-7357-0","article-title":"Comparison of monoclonal gammopathy of undetermined significance-associated neuropathy and chronic inflammatory demyelinating polyneuropathy patients","volume":"261","author":"Alkhawajah","year":"2014","journal-title":"J Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1045002","article-title":"Monoclonal gammopathies of clinical significance (MGCS): In pursuit of optimal treatment","volume":"13","author":"Oganesyan","year":"2022","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41572-018-0027-2","article-title":"Immune-mediated neuropathies","volume":"4","author":"Kieseier","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2022.05.002","article-title":"Therapies in autoimmune peripheral neuropathies beyond intravenous immunoglobulin, plasma exchange and corticosteroids: An analytical review","volume":"36","author":"Sivadasan","year":"2022","journal-title":"Transfus Med Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-378992","article-title":"How I treat POEMS syndrome","volume":"119","author":"Dispenzieri","year":"2012","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.0198","article-title":"Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: The ORCHARRD study","volume":"35","author":"van Imhoff","year":"2017","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16190","article-title":"Impact of 2021 European Academy of Neurology\/Peripheral Nerve Society diagnostic criteria on diagnosis and therapy of chronic inflammatory demyelinating polyradiculoneuropathy variants","volume":"31","author":"De Lorenzo","year":"2024","journal-title":"Eur J Neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2020.e04230","article-title":"Severe CIDP-MGUS responsive to rituximab","volume":"6","author":"Posa","year":"2020","journal-title":"Heliyon"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10646-y","article-title":"Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis","volume":"269","author":"Hu","year":"2022","journal-title":"J Neurol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00518-0","article-title":"The development of ofatumumab, a fully human anti-CD20 monoclonal antibody for practical use in relapsing multiple sclerosis treatment","volume":"12","author":"Hauser","year":"2023","journal-title":"Neurol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a032037","article-title":"B-cell therapies in multiple sclerosis","volume":"9","author":"Sabatino","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30144-9","article-title":"Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"18","author":"Bunschoten","year":"2019","journal-title":"Lancet Neurol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2021.11.008","article-title":"Refractory CIDP successfully treated with autologous haematopoietic stem cell transplantation in a patient with monoclonal gammopathy of undetermined significance (MGUS) and rheumatoid arthritis","volume":"32","author":"Lopes","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"B15","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.anai.2023.01.018","article-title":"Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab","volume":"130","author":"Athni","year":"2023","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1633753\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:48:29Z","timestamp":1776059309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1633753\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":15,"alternative-id":["10.3389\/fimmu.2026.1633753"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1633753","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"article-number":"1633753"}}